|
25 Jun 2019 |
Dompé Announces First Patient Enrollment in Phase 2b Clinical Trial Investigating Novel Mechanism of Action in Moderate to Severe Dry Eye Disease
|
|
24 Jun 2019 |
Athenex Announces U.S. FDA Allowance of Investigational New Drug Application for PT01 (Pegtomarginase)
|
|
22 Jun 2019 |
FDA Approves BOTOX® (onabotulinumtoxinA) for Pediatric Patients with Upper Limb Spasticity
|
|
22 Jun 2019 |
FDA Approves New Drug Application for Vyleesi™ (bremelanotide injection)
|
|
21 Jun 2019 |
Esperoct® (turoctocog alfa pegol, N8-GP) approved in the EU
|
|
21 Jun 2019 |
Camurus Receives IND Acceptance From the FDA to Enter Phase 3 with CAM2029 for Treatment of Acromegaly
|
|
21 Jun 2019 |
Medicenna Presents New Preclinical Results For its IL-2 Superkine Platform, MDNA109
|
|
21 Jun 2019 |
Horizon Therapeutics plc Initiates MIRROR Randomized Controlled Trial Evaluating KRYSTEXXA® (pegloticase injection) in Combination with Methotrexate to Increase Response Rates and Duration of Therapy
|
|
20 Jun 2019 |
Arch Biopartners Announces Start of Phase I Human Trial for Metablok
|
|
19 Jun 2019 |
Kleo Pharmaceuticals Announces a CD38 Targeting Antibody Recruiting Molecule (ARM™) to Treat Multiple Myeloma as the First Clinical Candidate in its Partnership with PeptiDream
|
|
19 Jun 2019 |
Medicenna Presents Preliminary Top-Line Clinical Results from their Phase 2b Trial of MDNA55 in Recurrent Glioblastoma
|
|
18 Jun 2019 |
Promedior Presents Positive Data from a Phase 2 Study of PRM-151 in Myelofibrosis Patients Failed/Ineligible for Ruxolitinib at the 24th European Hematology Association Annual Congress
|
|
18 Jun 2019 |
Eiger Announces Breakthrough Therapy Designation Granted by FDA for Avexitide for Treatment of Post-Bariatric Hypoglycemia (PBH)
|
|
18 Jun 2019 |
FDA approves Victoza® for the treatment of type 2 diabetes in children and adolescents aged 10-17 years
|
|
13 Jun 2019 |
First-in-Human Data Presented from Phase 1a Study of NKTR-358, a Novel T Regulatory Cell Stimulator, at Annual European Congress of Rheumatology
|
|
13 Jun 2019 |
Noveome Biotherapeutics, Inc. Announces the First Patient Dosed in Phase 2 Open Label Clinical Trial Evaluating Topical Ocular Delivery of ST266 For the Treatment of Persistent Corneal Epithelial Defects
|
|
13 Jun 2019 |
Savara Announces Results of IMPALA, a Phase 3 Study of Molgradex for the Treatment of Autoimmune Alveolar Pulmonary Proteinosis (aPAP)
|
|
12 Jun 2019 |
OrthoTrophix Presents Clinical Data at European Congress of Rheumatology
|
|
12 Jun 2019 |
Oral semaglutide demonstrated cardiovascular safety in people with type 2 diabetes and established cardiovascular disease or high cardiovascular risk in PIONEER 6 trial
|
|
10 Jun 2019 |
Avacta Group plc Hits Clinical Candidate Selection Milestone for Affimer PD-L1 Inhibitor
|
|
10 Jun 2019 |
Lilly's ultra rapid lispro provided similar A1C reductions compared to Humalog (insulin lispro), with superior post-meal blood glucose reductions
|
|
10 Jun 2019 |
Soliqua® Phase 3 results significantly lowered blood sugar levels compared to GLP-1 receptor agonist treatments
|
|
09 Jun 2019 |
Lilly's tirzepatide demonstrates benefits in data presented at the American Diabetes Association's 79ᵗʰ Scientific Sessions
|
|
09 Jun 2019 |
Dance Biopharm Presents Encouraging Data from Phase 2 Clinical Trial of Dance 501 Inhaled Insulin Therapy at American Diabetes Association Meeting
|
|
09 Jun 2019 |
Oral semaglutide showed superior reductions in blood sugar vs Jardiance® and non-inferior blood sugar reductions vs Victoza® in adults with type 2 diabetes at 26 weeks
|
